Actuarial science

Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN”

Friday, September 18, 2020 - 1:30am

Humanigen also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • Humanigen also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares at the public offering price, less underwriting discounts and commissions.
  • J.P. Morgan and Jefferies are acting as joint book-running managers for the offering.
  • Bryan, Garnier & Co. is acting as the European lead manager and H.C. Wainwright & Co., National Securities Corporation and Roth Capital Partners are acting as co-managers for the offering.
  • As previously announced, Humanigens stock will commence trading on the Nasdaq Capital Market on Friday, September 18, 2020, under the symbol HGEN.

Athene Holding Ltd. Appoints Lynn Swann to Board of Directors

Thursday, September 17, 2020 - 10:30pm

Athene Holding Ltd. (Athene) (NYSE: ATH), a leading provider of retirement savings products, announced today the appointment of Lynn Swann as an independent member of Athenes board of directors, effective immediately.

Key Points: 
  • Athene Holding Ltd. (Athene) (NYSE: ATH), a leading provider of retirement savings products, announced today the appointment of Lynn Swann as an independent member of Athenes board of directors, effective immediately.
  • Lynn Swann is President of Swann, Inc., a marketing and consulting firm he founded in 1976.
  • We are pleased to welcome Lynn to our board of directors, said Jim Belardi, CEO of Athene.
  • Athenes principal subsidiaries include Athene Annuity & Life Assurance Company, a Delaware-domiciled insurance company, Athene Annuity and Life Company, an Iowa-domiciled insurance company, Athene Annuity & Life Assurance Company of New York, a New York-domiciled insurance company and Athene Life Re Ltd., a Bermuda-domiciled reinsurer.

Global Anti-Asthmatics and COPD Drugs Market Forecast to Reach $83.8 billion by 2023

Thursday, September 17, 2020 - 9:30pm

Where is the largest and fastest-growing market for the anti-asthmatics and COPD drugs market?

Key Points: 
  • Where is the largest and fastest-growing market for the anti-asthmatics and COPD drugs market?
  • The global anti-asthmatics and COPD drugs market is expected to grow from $52 billion in 2019 to $77.3 billion in 2020 at a compound annual growth rate (CAGR) of 48.8%.
  • The market is then expected to grow at a CAGR of 5.7% from 2021 and reach $83.8 billion in 2023.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies.

Global Serological Transplant Diagnostics Market 2020-2027: U. S. Market is Estimated at $90.8 Million, While China is Forecast to Grow at 4.9% CAGR

Thursday, September 17, 2020 - 7:30pm

DUBLIN, Sept. 17, 2020 /PRNewswire/ -- The "Serological Transplant Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 17, 2020 /PRNewswire/ -- The "Serological Transplant Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Serological Transplant Diagnostics estimated at US$335.8 Million in the year 2020, is projected to reach a revised size of US$401.4 Million by 2027, growing at a CAGR of 2.6% over the period 2020-2027.
  • Reagents & Accessories, one of the segments analyzed in the report, is projected to record 2.8% CAGR and reach US$310.6 Million by the end of the analysis period.
  • The U. S. Market is Estimated at $90.8 Million, While China is Forecast to Grow at 4.9% CAGR
    The Serological Transplant Diagnostics market in the U. S. is estimated at US$90.8 Million in the year 2020.

LDPE Material Segment to Fuel Notable Growth in Stand-Up Pouch Market from 2018 to 2026: TMR

Thursday, September 17, 2020 - 5:30pm

ALBANY, N.Y, Sept. 17, 2020 /PRNewswire/ -- From 2018 to 2026, multiple growth factors are set to drive new opportunities to the global stand up pouches market landscape.

Key Points: 
  • ALBANY, N.Y, Sept. 17, 2020 /PRNewswire/ -- From 2018 to 2026, multiple growth factors are set to drive new opportunities to the global stand up pouches market landscape.
  • It is worth noting here that over the stated period, a robust CAGR of 5.4% will be charted.
  • And, of the many things this will translate on to the growth charts, one of the most significant will be market worth.
  • As per Transparency Market Research, "The global stand-up pouches market will witness growth as an outcome of increasing demand from a number of end-use industries.

Carbon Therapy Segment in Particle Therapy Market to Grow at Exponential Growth Rate from 2018 to 2026: TMR

Thursday, September 17, 2020 - 4:30pm

ALBANY, N.Y., Sept. 17, 2020 /PRNewswire/ --From 2018 to 2026, the compound annual growth rate (CAGR) of global particle therapy market is anticipated to be 8%.

Key Points: 
  • ALBANY, N.Y., Sept. 17, 2020 /PRNewswire/ --From 2018 to 2026, the compound annual growth rate (CAGR) of global particle therapy market is anticipated to be 8%.
  • In the year 2017, it is quite pertinent to note, the market valuation stood at USD 364.8 million.
  • Request a sample of the study https://www.transparencymarketresearch.com/sample.php
    Competitive Landscape of Global Particle Therapy Market:
    The vendor landscape is marked by growth strategies that are shaping the future dynamics of the market.
  • For the study, the Particle Therapy market has been segmented as follows:

Global Neuromorphic Chips Market to Reach $10.4 Billion by 2027 - ResearchAndMarkets.com

Thursday, September 17, 2020 - 4:42pm

Amid the COVID-19 crisis, the global market for Neuromorphic Chips estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$10.4 Billion by 2027, growing at a CAGR of 24.2% over the analysis period 2020-2027.

Key Points: 
  • Amid the COVID-19 crisis, the global market for Neuromorphic Chips estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$10.4 Billion by 2027, growing at a CAGR of 24.2% over the analysis period 2020-2027.
  • The Neuromorphic Chips market in the U.S. is estimated at US$682.1 Million in the year 2020.
  • China, the world’s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2027 trailing a CAGR of 23.6% over the analysis period 2020 to 2027.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.2 Billion by the year 2027.

Patient Safety and Risk Management Software Markets - Global Forecast to 2025 - ResearchAndMarkets.com

Thursday, September 17, 2020 - 4:02pm

The "Patient Safety and Risk Management Software: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Patient Safety and Risk Management Software: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The market for patient safety and risk management software is expected to experience high growth during the forecast period.
  • These factors positively affect market growth for patient safety and risk management software over the forecast period.
  • The goal of risk management in healthcare services is to ensure patient safety by identifying and measuring risks to patient safety and organizational growth.

GSTS Awarded Contract to Support Maritime Risk Mitigation

Thursday, September 17, 2020 - 4:00pm

GSTS will leverage OCIANA's robust risk management capabilities to support maritime risk mitigation.

Key Points: 
  • GSTS will leverage OCIANA's robust risk management capabilities to support maritime risk mitigation.
  • This contract award will enable the Department of National Defence to test OCIANA, an AI-based Maritime Information Management platform.
  • "Protecting all of Canada's maritime approaches and points of entry, from coast to coast to coast, OCIANA's maritime AI-based risk management capabilities will support real-time decision-making and response capabilities," said Richard Kolacz, GSTS CEO.
  • In this case, we have developed a unique AI solution to support the identification of vessels representing a potential COVID-19 risk in addition to the security risk parameters.

AM Best Affirms Credit Ratings of ERGO Insurance Pte. Ltd.

Thursday, September 17, 2020 - 3:22pm

The Credit Ratings (ratings) of ERGO Insurance reflect its balance sheet strength, which AM Best categorises as strong, as well as its marginal operating performance, limited business profile and appropriate enterprise risk management (ERM).

Key Points: 
  • The Credit Ratings (ratings) of ERGO Insurance reflect its balance sheet strength, which AM Best categorises as strong, as well as its marginal operating performance, limited business profile and appropriate enterprise risk management (ERM).
  • ERGO Insurance is a wholly owned subsidiary of ERGO Group AG (ERGO Group), which is the primary insurance arm of Munich Re.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Bests Credit Ratings .
  • For information on the proper media use of Bests Credit Ratings and AM Best press releases, please view Guide for Media - Proper Use of Bests Credit Ratings and AM Best Rating Action Press Releases .